Cognitive impairment in schizophrenia represents one of the main obstacles to clinical and
functional recovery. This expert group paper brings together experts in schizophrenia …

Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs)
have revolutionized psychiatric care in terms of facilitating discharge from hospital and …

Understanding how the brain translates a structured sequence of sounds, such as music,
into a pleasant and rewarding experience is a fascinating question which may be crucial to …

Despite effective pharmacological treatments for psychotic symptoms (eg, hallucinations,
delusions), functional outcomes for people with psychotic disorders are often disappointing …

The discovery in the 1950s that antipsychotic medication could dramatically improve the
positive (and in some cases negative) symptoms of severe psychotic disorders led to …

Antipsychotic polypharmacy remains prevalent; it has probably increased for the treatment of
schizophrenia in real-world clinical settings. The current evidence suggests some clinical …

Background Antipsychotic-associated side effects are well known and represent a significant
treatment challenge. Still, few large studies have investigated the overall side effect burden …

This naturalistic study analysed the association between cumulative lifetime antipsychotic
dose and cognition in schizophrenia after an average of 16.5 years of illness. Sixty …

Aripiprazole, brexpiprazole and cariprazine differ from all other second-generation
antipsychotics due to partial agonism at the dopamine D2 and D3 receptors. In contrast to …

Cannabidiol (CBD), a principal phytocannabinoid constituent, has demonstrated
antipsychotic properties in recent clinical trials. While it has also been suggested a …